ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Safety and efficacy of apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD): a prospective, single-arm, multicenter, phase IV study

Li, Jin; Qin, Shukui*; Wen, Lu; Wang, Junsheng; Deng, Wenying; Guo, Weijian; Jia, Tongfu; Jiang, Da; Zhang, Guifang; He, Yifu; Ba, Yi; Zhong, Haijun; Wang, Lin; Lin, Xiaoyan; Yang, Jianwei; Zhao, Jun; Bai, Yuxian; Wu, Xiangyuan; Gao, Feng; Sun, Guogui; Wu, Yongjuan; Ye, Feng; Wang, Qiong; Xie, Zhong; Yi, Tienan; Huang, Yong; Yu, Guohua; Lu, Lin; Yuan, Ying; Li, Wei; Liu, Likun; Sun, Yuping; Sun, Ying; Yin, Lifeng; Hou, Zhiguo复旦大学; 广东医学院; 吉林大学; 哈尔滨医科大学; 河北医科大学; 浙江大学; 郑州大学; 同济大学; 厦门大学; 中山大学; 中国科学院研究生院; 1
BMC Medicine2023-5-5DOI: 10.1186/s12916-023-02841-7
1被引16阅读
引用收藏
分享

摘要

BackgroundApatinib, a highly selective VEGFR2 inhibitor, significantly improved efficacy versus placebo as a third- and later-line treatment for advanced gastric cancer in phase 2 and 3 trials. This prospective, single-arm, multicenter phase IV AHEAD study was conducted to verify the safety and efficacy of apatinib in patients with advanced or metastatic gastric or gastroesophageal adenocarcinoma after at least two lines of systematic therapy in clinical practice settings.MethodsPatients with advanced gastric cancer who had previously failed at least two lines of chemotherapy received oral apatinib until disease progression, death or unacceptable toxicity. The primary endpoint was safety. The secondary endpoints included objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS) and overall survival (OS). Adverse events were summarized by the incidence rate. Median OS and PFS were estimated using the Kaplan-Meier method. ORR, DCR, OS at 3 and 6 months, and PFS at 3 and 6 months were calculated, and their 95% CIs were estimated according to the Clopper-Pearson method.ResultsBetween May 2015 and November 2019, a total of 2004 patients were enrolled, and 1999 patients who received at least one dose of apatinib were assessed for safety. In the safety population, 87.9% of patients experienced treatment-related adverse events (TRAEs), with the most common hypertension (45.2%), proteinuria (26.5%), and white blood cell count decreased (25.3%). Additionally, 51% of patients experienced grade >= 3 TRAEs. Fatal TRAEs occurred in 57 (2.9%) patients. No new safety concerns were reported. Among the 2004 patients included in the intention-to-treat population, the ORR was 4.4% (95% CI, 3.6-5.4%), and DCR was 35.8% (95% CI, 33.7-38.0%). The median PFS was 2.7 months (95% CI 2.2-2.8), and the median OS was 5.8 months (95% CI 5.4-6.1).ConclusionsThe findings in the AHEAD study confirmed the acceptable and manageable safety profile and clinical benefit of apatinib in patients with advanced gastric cancer as a third- or later-line of treatment.

学科与关键词

关键词
Advanced gastric cancerApatinibThird- and later-line treatmentPhase IV studySafetyEfficacy
相关
加载中…
  • Evaluation of second-line apatinib plus irinotecan as a treatment for advanced gastric adenocarcinoma or gastroesophageal conjunction adenocarcinoma: a prospective, multicenter phase II trial
    Qu, Jinglei; He, Xin; Luo, Ying; Yu, Ping; Chen, Ying; Liu, Jing; Wang, Xin; Wang, Chang; Liang, Tingting; Bai, Yuxian; Han, Yu; Man, Li; Leng, Chuanchun; Zhou, Caiyun; He, Lijie; Liu, Yunpeng*; Qu, Xiujuan*Frontiers in Oncology, 2023, 13: 1072943.
  • Multiple-dose up-titration study to evaluate the pharmacokinetics, safety and antitumor activity of apatinib in advanced gastric adenocarcinoma
    Wang, Yonggang; Wang, Chang; Zhang, Yanqiao; Hao, Jiqing; Yang, Nong; Wang, Jvfeng; Peng, Min; Liu, Tianshu; Zhang, Guifang; Zhan, Xianbao; Zeng, Shan; Zhang, Yifan; Gao, Yong*; Yao, Yang*Frontiers in Oncology, 2022, 12: 876899.被引 1
  • Efficacy and safety of apatinib in patients with untreated or chemotherapy-refractory soft tissue sarcoma: a multicenter, phase 2 trial
    Yu, Wenxi; Zhang, Hongmei; Chen, Jing; Zhang, Xing; Chen, Yong; Qu, Guofan; Huang, Gang; Zhou, Yuhong; Ye, Ting; Fan, Zhengfu*; Yao, Yang*Annals of Translational Medicine, 2022, 10(18): 981.被引 4
查看全部 →

发表信息

论文状态
公开发表
期刊
BMC Medicine
发表日期
2023-05-05
卷期
第 21 卷, 第 1 期
页码
173
DOI
10.1186/s12916-023-02841-7
语言
ENGLISH
成果收录
SCIE
资助标注
Jiangsu Hengrui Pharmaceuticals

作者

  • L

    Li, Jin (第一作者)

    tongji univ

  • Q

    Qin, Shukui (通讯)

    nanjing univ chinese med

查看全部 35 位作者收起作者
  • W

    Wen, Lu

    shanxi prov canc hosp

  • W

    Wang, Junsheng

  • D

    Deng, Wenying

    zhengzhou univ

  • G

    Guo, Weijian

    fudan univ

  • J

    Jia, Tongfu

  • J

    Jiang, Da

    hebei med univ

  • Z

    Zhang, Guifang

  • H

    He, Yifu

    1 · 2 · chinese acad sci, inst canc · fujian canc hosp · fujian med univ · guangdong med univ · harbin med univ · hubei univ arts & sci · jilin univ · sun yat sen univ · tianjin med univ canc inst & hosp · univ chinese acad sci · weifang peoples hosp · xiamen univ · zhejiang canc hosp · zhejiang univ · ustc

  • B

    Ba, Yi

  • Z

    Zhong, Haijun

  • W

    Wang, Lin

    nanjing univ chinese med

  • L

    Lin, Xiaoyan

  • Y

    Yang, Jianwei

  • Z

    Zhao, Jun

  • B

    Bai, Yuxian

  • W

    Wu, Xiangyuan

  • G

    Gao, Feng

  • S

    Sun, Guogui

  • W

    Wu, Yongjuan

  • Y

    Ye, Feng

  • W

    Wang, Qiong

  • X

    Xie, Zhong

  • Y

    Yi, Tienan

  • H

    Huang, Yong

  • Y

    Yu, Guohua

  • L

    Lu, Lin

  • Y

    Yuan, Ying

  • L

    Li, Wei

  • L

    Liu, Likun

  • S

    Sun, Yuping

  • S

    Sun, Ying

  • Y

    Yin, Lifeng

  • H

    Hou, Zhiguo

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417